Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus
- 19 June 2003
- journal article
- Published by Elsevier in Antiviral Research
- Vol. 59 (3) , 155-161
- https://doi.org/10.1016/s0166-3542(03)00109-8
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Efficacies of Entecavir against Lamivudine-Resistant Hepatitis B Virus Replication and Recombinant Polymerases In VitroAntimicrobial Agents and Chemotherapy, 2002
- Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virusAntiviral Research, 2002
- Potent Efficacy of Entecavir (BMS-200475) in a Duck Model of Hepatitis B Virus ReplicationAntimicrobial Agents and Chemotherapy, 2002
- Long‐Term Entecavir Treatment Results in Sustained Antiviral Efficacy and Prolonged Life Span in the Woodchuck Model of Chronic Hepatitis InfectionThe Journal of Infectious Diseases, 2001
- Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infectionHepatology, 2001
- A phase II study of entecavir vs lamivudine in adults with chronic hepatitis BJournal of Hepatology, 2001
- Animal Models for HBV Infections — Transgenic MicePublished by Elsevier ,1999
- Efficacy of the Carbocyclic 2′-Deoxyguanosine Nucleoside BMS-200475 in the Woodchuck Model of Hepatitis B Virus InfectionAntimicrobial Agents and Chemotherapy, 1998
- Evaluation of Anti-Hepatitis B Virus (HBV) Drugs Using the HBV Transgenic Mouse: Application of the Semiquantitative Polymerase Chain Reaction (PCR) for Serum HBV DNA to Monitor the Drug EfficacyBiochemical and Biophysical Research Communications, 1997
- Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virusAntimicrobial Agents and Chemotherapy, 1997